Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 49Carcinoma, Basal Cell 12Neoplasm Metastasis 9Lymphoma, T-Cell, Cutaneous 9Skin Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Lymphoma, T-Cell 5Colorectal Neoplasms 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Mycosis Fungoides 4Lymphoma 4Lung Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Sarcoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Follicular 3Keratosis, Actinic 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2

Interventions

Lidocaine 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pruritus × Biopsy × Dermatologic × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡